PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

PHASE4CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
Hemophilia A
Interventions
DRUG

Intravenous infusions of Xyntha

Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.

Trial Locations (15)

100045

Beijing Children's hospital, Beijing

200025

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine/Hematology Department, Shanghai

200040

Department of Hematology/Children's Hospital of Shanghai, Shanghai

215006

Department of Hematology,The First Affiliated Hospital of Soochow University, Suzhou

250014

Blood Center of Shandong Province, Jinan

300020

Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology), Tianjin

330006

Department of Hematology,Jiangxi Provincial People's Hospital, Nanchang

400010

The second affiliated hospital of chongqing medical university, Chongqing

400014

Children's Hospital of Chongqing Medical University, Chongqing

430030

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan

450003

Henan Provincial People's Hospital, Zhengzhou

510515

Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

610073

Chengdu Women's and Children's Central Hospital, Chengdu

650032

Department of Hematology,The First Affiliated Hospital of Kunming Medical University, Kunming

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02492984 - PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A | Biotech Hunter | Biotech Hunter